Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Blood (2024) 143 (26): 2722–2734.

https://doi.org/10.1182/blood.2023023447

Published: 2024

Includes: Supplemental data

Journal Articles

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Vivian Irizarry Gatell, Denise Kalos, Joseph A. Pidala, Hany Elmariah, Farhad Khimani, Asmita Mishra, Taiga Nishihori, Michael D. Jain, Michael Neider, Lia Perez, Sayeef Mirza, Bijal D. Shah, Leidy Lismeris Isenalumhe, Nelli Bejanyan, Aleksandr Lazaryan, Rawan Faramand

Blood (2023) 142 (Supplement 1): 2830.

https://doi.org/10.1182/blood-2023-180321

Published: 2023

Journal Articles

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Ramzi Hamouche, Francine M. Foss, Sayeef Mirza, Mengyang Di, Iris Isufi, Noffar Bar, Lohith Gowda, Sarah Perreault, Kenneth Roberts, Stuart Seropian, Tarsheen Sethi

Blood (2023) 142 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2023-189414

Published: 2023

Journal Articles

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Blood (2023) 142 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2023-181762

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

Tariq Kewan, Sayeef Mirza, Alexander B Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean X Gu, Yuxin Liu, Jennifer Vanoudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2023) 142 (Supplement 1): 2132.

https://doi.org/10.1182/blood-2023-187295

Published: 2023

Journal Articles

CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma

Ruifeng Sun, Jaewoong Lee, Tim Wartewig, Mark E. Robinson, Alberto Bigogno, David Fonseca Arce, Abu-Sayeef Mirza, Andrew Takeda, Lars Klemm, Vivasvan Vykunta, Brian Shy, Alexander Marson, Markus Müschen

Blood (2022) 140 (Supplement 1): 5975–5976.

https://doi.org/10.1182/blood-2022-170076

Published: 2022

Journal Articles

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Abu-Sayeef Mirza, Alexander Pine, Yusuf Rasheed, Ramzi Hamouche, Etienne Leveille, George Goshua, Sean Gu, Yuxin Liu, Jennifer VanOudenhove, Noffar Bar, Natalia Neparidze, Francine M. Foss, Lohith Gowda, Iris Isufi, Stephanie Halene, Alfred I Lee, Stuart Seropian

Blood (2022) 140 (Supplement 1): 10410–10412.

https://doi.org/10.1182/blood-2022-168374

Published: 2022

Journal Articles

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Abu-Sayeef Mirza, Chitra Hosing, Francine M. Foss, Soyoung Kim, Amy Moskop, Temitope Oloyede, Sairah Ahmed, Peiman Hematti, Cameron J. Turtle, Marcelo C. Pasquini, Lohith Gowda

Blood (2022) 140 (Supplement 1): 4633–4635.

https://doi.org/10.1182/blood-2022-163750

Published: 2022

Journal Articles

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Frederick L. Locke, Caron Jacobson, Long Ma, Hua Dong, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Abu-Sayeef Mirza, Sarah Nikiforow, Hairong Xu, Marcelo C Pasquini

Blood (2021) 138 (Supplement 1): 530.

https://doi.org/10.1182/blood-2021-149679

Published: 2021

Journal Articles

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Mohammad O Hussaini, MD, Jinming Song, MD PhD, Andrew T Kuykendall, MD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Sayeef Mirza, MDMPH, Ling Zhang, MD

Blood (2019) 134 (Supplement_1): 5442.

https://doi.org/10.1182/blood-2019-128997

Published: 2019

Journal Articles

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Sayeef Mirza, MDMPH, Ankita Tandon, DO, Dakota Jenneman, MD, Shu Cao, MD, Ambuj Kumar, MD MPH, Michelle R. Kidd, PharmD, Farhad Khimani, MD, Asmita Mishra, MD, Hien D. Liu, MD, Taiga Nishihori, MD, Lia Perez, MD, Nelli Bejanyan, MD, Joseph Pidala, MD, Michael Nieder, MD, Hany Elmariah, MD MS

Blood (2019) 134 (Supplement_1): 5673.

https://doi.org/10.1182/blood-2019-127370

Published: 2019

Journal Articles

Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience

Blood (2018) 132 (Supplement 1): 5880.

https://doi.org/10.1182/blood-2018-99-120332

Published: 2018

Journal Articles

Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience

Sayeef Mirza, MD MPH, Seongseok Yun, MD PhD, Najla Al Ali, M.Sc, Maher Elharake, MD, Nathan Visweshwar, MD, Daniel Schwartz, Katherine Robinson, MD, Ethan Nowell, BS, Grace Engle, Ibraahim Badat, Thomas Brimer, MD, Amra Kuc, Ashton Sequeira, MD, Sabbir Mirza, Dhiraj Sikaria, Jesus Diaz Vera, Noah Hackney, Rami S. Komrokji, MD, Michael Jaglal, MD

Blood (2018) 132 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2018-99-117545

Published: 2018

Journal Articles

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, Rami S. Komrokji, MD, David A Sallman, MD, Andrew Kuykendall, MD, Eric Padron, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5270.

https://doi.org/10.1182/blood.V130.Suppl_1.5270.5270

Published: 2017

Journal Articles

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

Mohammad Omar Hussaini, MD, Jinming Song, MD PhD, David A Sallman, MD, Eric Padron, MD, Rami S. Komrokji, MD, Andrew Kuykendall, MD, Sayeef Mirza, MD MPH, Ling Zhang, MD

Blood (2017) 130 (Supplement 1): 5275.

https://doi.org/10.1182/blood.V130.Suppl_1.5275.5275

Published: 2017

NARROW

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Clinical Outcomes of Adults Undergoing Allogeneic Stem Cell Transplant for Secondary Acute Lymphoblastic Leukemia

Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience

Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)

CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma

Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel

Impact of Age on Outcomes after CD19 Directed CAR T Cell Therapy for Large B Cell Lymphomas: Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR)

Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction

Genetic and Clinical Features of Chronic Myelmonocytic Leukemia with Fibrosis

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Incidence, Risk, and Markers of Thrombosis in AML Patients - Single Institution Experience

Validation of the Khorana Score in Acute Myeloid Leukemia Patients: A Single Institution Experience

TP53 Mutations Are a Rare Event in Primary Myelofibrosis, Associated with TET2 Mutations, and Suggest Poor Clinical Outcome

Presence of MDS-Related Cytogenetic Abnormalities Predicts Worse Outcomes in Primary Myelofibrosis Compared to Patients with Del(13q)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only